Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases - sprookjes - yvandenbroek - TriplyDB

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases

http://www.wikidata.org/entity/Q26864098

about

Hepatic manifestations of non-steroidal inflammatory bowel disease therapy Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance Chronic liver injury induced by drugs: a systematic review.Comparison of Laboratory Data of Acute Cholangitis Patients Treated with or without Immunosuppressive Drugs.Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease.Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management.Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases Infliximab-associated fulminant hepatic failure in ulcerative colitis: a case report.Drug-Induced Liver Injury: Pattern Recognition and Future Directions.Hepatotoxicity Associated with the Use of Anti-TNF-α Agents Hepatitis and Lupus-Like Syndrome during Infliximab Therapy for Psoriasis.Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy.Liver Injury Secondary to Anti-TNF-Alpha Therapy in Inflammatory Bowel Disease: A Case Series and Review of the Literature.Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis.Drug-induced liver injury: what was new in 2013?Drug-induced liver injury: an overview over the most critical compounds.Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.Hepatic manifestations of inflammatory bowel diseases.Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature.The histopathological evaluation of drug-induced liver injury.A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study.Andrographolide ameliorates d-galactosamine/lipopolysaccharide-induced acute liver injury by activating Nrf2 signaling pathway.Infliximab reduces peripheral inflammation, neuroinflammation, and extracellular GABA in the cerebellum and improves learning and motor coordination in rats with hepatic encephalopathy.Role of glucocorticoid-induced leucine zipper (GILZ) in inflammatory bone loss.New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease.Detection of liver injury in IBD using transient elastography.Development of a rat model of D-galactosamine/lipopolysaccharide induced hepatorenal syndrome.Hepatotoxicity of anti-TNF agents.Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review.Immune Checkpoint Inhibitor-Associated Colits and Hepatitis

P2860

Q26773684-49EB39B5-8DBE-4914-B346-578A7DBE4D4C Q28076505-216B4EC3-7B38-449D-B2DE-BC928204582F Q28538041-5FD64440-D36C-4A7A-91DD-B73EB4BCA794 Q30278737-F806F615-6701-44F5-AFD7-73B9CF1D88B3 Q30801435-A59EF629-53DF-4928-861C-031CB973EDE6 Q33563872-D2E0FBAB-4BF3-4EFB-A0AC-939D876E3063 Q33654733-6DC61612-07ED-40D3-8CD8-5966854F43AA Q33845138-E345F552-C1C5-4CF7-8ED4-788BCDF83A62 Q35526652-FA2DFAA8-4A33-49E1-9C0F-0258E11F5747 Q35783976-745F049F-9595-49F7-BFE4-E403503FF19D Q36232337-5E7898E8-BE79-4A31-8A6A-87C544107867 Q36412863-A83A6F89-6A71-4CEA-A7BA-F3F6FC6A9470 Q36576535-9D9BEC8E-E23D-4157-9EFD-E7F7E8A6E08F Q37151335-042BAE08-5FF4-4E36-89E8-773D415E1B98 Q37317444-22665AC8-C86F-4A8F-8863-0D1D457CF91E Q37505690-B9C4BBD2-9AD9-4C4B-8B3B-6A8D2E171718 Q37664177-4E01C40E-FA9D-465E-A7C5-5F5DA81126F6 Q38175465-77D1B038-5169-42C7-9AE2-6AD48079D133 Q38205591-CBC267F2-033F-4BCF-8BD7-0A7191CF8585 Q38331202-5BCE2DF8-0E39-4CBA-82B9-5B46306BF88E Q38630959-C2526F03-371F-471A-BFDF-05BD64E1A2D2 Q38814158-E09B9F18-9A52-4657-976F-85CE3C85FE71 Q38824550-14DE8C95-DE24-483C-9E26-E818E03E79C1 Q39037640-5B12F74E-5069-4A09-9538-B2D708AFD1DD Q39263506-D0162A82-C60D-4E24-B720-ECD6F2D843DD Q40229044-14675BA8-BEF2-4921-9238-735392B377EC Q41085679-A88E60CF-8630-4688-B09D-1FD8067ABA0E Q41236945-C2382A21-B470-48F7-A6C8-18807110FDF6 Q41256627-35BE45E5-784C-47F8-9759-A5D6F3D1A11B Q42228367-B912C82C-B714-43DC-AC62-90F7146F87A6 Q43197363-13699092-7946-48D0-943B-485D750A4833 Q46114632-98360C51-F6CD-4BBD-87F7-FA3958F9C987 Q55114620-5804B088-D9EE-4D60-B87A-EAEC2443F726 Q58721137-198D31E4-02D0-465F-AF92-16D43DB3A52B

P2860

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases

http://www.wikidata.org/entity/Q26864098

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases

@ast

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases

@en

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases

@nl

type

label

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases

@ast

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases

@en

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases

@nl

prefLabel

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases

@ast

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases

@en

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases

@nl

P1433

Q26864098-8A7B785B-5FDF-4A07-9AAA-9359B5D62194

P1476

Q26864098-FB049C55-89B5-416A-8065-271153DB545F

P2093

Q26864098-3304AD2D-0173-435D-B1AA-3DEDE9886106

Q26864098-43416A13-20FC-47C9-BBD5-8B8653AE70FF

Q26864098-61310F37-4DEB-454A-A107-D48AEF031DFA

Q26864098-8EDF2667-6914-405C-933E-05534F87C0D6

Q26864098-923A91AF-FB15-473B-99A9-CD8E73D981B6

Q26864098-9CF86FCE-A149-43C1-8EF8-F4B85A788EE8

Q26864098-C829BB87-7B33-41EC-BDD3-B7F68CD2DDBC

Q26864098-D3F412EB-E07E-4CDB-828D-E2A19FA7ED06

Q26864098-E6BBC703-DDA6-4184-97F5-4A6BD0FF0078

P2860

Q26864098-0BDDEDAE-7AFD-4DED-9655-756DD2A63F00

Q26864098-1BD0A1E2-3FCB-462A-828F-0C85D77562F4

Q26864098-2AA4BA65-9536-4773-B780-52B2EEF72EC8

Q26864098-351BE78C-3DB6-4996-AC27-A823B6FBEFFB

Q26864098-4119C06D-DABB-4E0F-9BDF-113898BBFFC1

Q26864098-42F9BBC9-50D9-41BB-B2E1-1792A86E5F2B

Q26864098-4985B2FA-928E-4EBB-B166-197E5A65D78D

Q26864098-601D247D-5555-41F5-A4C2-1F7B02F6F677

Q26864098-6653634B-CC0A-4C5E-80A4-5174DA60E797

Q26864098-68B7E0B8-CB25-42A6-B2D5-93138C8879A7

P304

Q26864098-BCD5581F-4597-468F-A8AC-B49FB7544178

P31

Q26864098-86F33491-1021-4B5A-9BAD-B70E8D48A147

P3181

Q26864098-C24F2AC6-D870-41AA-8C76-7D478C0CD677

P356

Q26864098-2A75C80F-B4F9-41B2-9AB1-89F1CCD6F8F6

P407

Q26864098-BEB300CE-7A66-4D96-B648-C0E5BDFA785E

P433

Q26864098-D49D8E49-F84C-464E-8649-106C946E12E5

P478

Q26864098-8809810E-412C-401C-A4D4-CB3A39C9F560

P50

Q26864098-49E2D964-441B-49C3-B9EE-60604633A973

Q26864098-98F97B8E-B0D8-4A8A-BA2D-D3F0949B86A4

P577

Q26864098-DE5058BD-E45A-4BEC-AC8B-632AB592E96E

P698

Q26864098-27E43DE7-29AD-431C-AC8E-15325AFFA6D7

P932

Q26864098-97B516BC-C826-4857-812F-5702CC0E822A

P3181

P356

J.CGH.2012.12.025

P1433

Clinical Gastroenterology and Hepatology

P1476

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases

@en

P2093

Clarissa Kum

http://www.w3.org/2001/XMLSchema#string

Herbert L Bonkovsky

http://www.w3.org/2001/XMLSchema#string

Jim Rochon

http://www.w3.org/2001/XMLSchema#string

Jose Serrano

http://www.w3.org/2001/XMLSchema#string

Maurizio Bonacini

http://www.w3.org/2001/XMLSchema#string

Paul H Hayashi

http://www.w3.org/2001/XMLSchema#string

Robert J Fontana

http://www.w3.org/2001/XMLSchema#string

Tim Davern

http://www.w3.org/2001/XMLSchema#string

US Drug-Induced Liver Injury Network

http://www.w3.org/2001/XMLSchema#string

P2860

Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop

Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.

A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis.

Infliximab-related hepatitis: discussion of a case and review of the literature.

Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review.

Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management.

Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis.

Drug-induced autoimmune hepatitis: clinical characteristics and prognosis.

[Acute drug-induced hepatitis during adalimumab and ibuprofen treatment].

Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.

P304

558-564.e3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3555307

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CGH.2012.12.025

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

David E. Kleiner

P577

2013-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23333219

http://www.w3.org/2001/XMLSchema#string

P932

3865702

http://www.w3.org/2001/XMLSchema#string